Hostname: page-component-78c5997874-j824f Total loading time: 0 Render date: 2024-11-16T23:56:42.275Z Has data issue: false hasContentIssue false
  • English
  • Français

Augmentation Strategies

Published online by Cambridge University Press:  07 November 2014

Michael E. Thase
Get access Rights & Permissions [Opens in a new window]

Extract

When patients do not respond to an initial course of antidepressant treatment, clinicians may opt for a number of alternatives. First, re-evaluating the diagnosis to make sure that no comorbidities were missed, and that the diagnosis of major depressive disorder (MDD) is accurate, particularly with respect to recognition of clinical features that might suggest previously unrecognized bipolarity or psychotic features. Secondly, clinicians should ensure that the patient has adhered to the recommended medication. When finally reaching the point of certainty or near certainty that the patient has not benefited from a truly adequate course of treatment lasting ≥8 weeks, the next major considerations usually are to either switch antidepressants or to augment the original choice of treatments. Lastly, selection of the most appropriate “next choice” strategy should take into account the tolerability of and degree of improvement observed with the initial antidepressant medications. Many clinicians prefer to switch patients who have poorer tolerability and minimal symptom improvement and try to augment therapy when the initial antidepressant has been well tolerated and resulted in some degree of symptom improvement.

Type
Expert Panel Supplement
Information
CNS Spectrums , Volume 14 , Issue S4: Pharmacologic and Therapeutic Strategies in Treatment-Resistant Depression , March 2009 , pp. 7 - 10
Copyright
Copyright © Cambridge University Press 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Thase, ME, Denko, T. Pharmacotherapy of mood disorders. Annu Rev Clin Psychol. 2008;4:53–91.CrossRefGoogle ScholarPubMed
2.Thase, ME, Schutte, AJ, van der flier, S, Heukels, A. Remission with mirtazapine versus SSRIs: a meta-analysis on data of more than 2500 depressed patients treated in randomised controlled trials. J Affect Disord. 2004;78 (suppl 1):S136.Google Scholar
3.Rush, AJ, Trivedi, MH, Wisniewski, SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006;354(12):1231–1242.CrossRefGoogle ScholarPubMed
4.Ruhe, HG, Huyser, J, Swinkels, JA, Schene, AH. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry. 2006;67(12):1836–1855.Google Scholar
5.Thase, ME. Therapeutic alternatives for difficult-to-treat depression: a narrative review of the state of the evidence. CNS Spectr. 2004;9(11):808–816, 818–821.CrossRefGoogle ScholarPubMed
6.Fava, M, Rush, AJ, Alpert, JE, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry. 2008;165(3):342–351.CrossRefGoogle ScholarPubMed
7.Poirier, MF, Boyer, P. Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison. Br J Psychiatry. 1999;175:12–16.Google Scholar
8.Sussman, N. Anxiolytic antidepressant augmentation. J Clin Psychiatry. 1998;59(suppl 5):42–48; discussion 49–50.Google Scholar
9.Fava, M, Thase, ME, DeBattista, C, Doghramji, K, Arora, S, Hughes, RJ. Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness. Ann Clin Psychiatry. 2007;19(3):153–159.CrossRefGoogle ScholarPubMed
10.Thase, ME, Fava, M, DeBattista, C, Arora, S, Hughes, RJ. Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension study. CNS Spectr. 2006;11(2):93–102.CrossRefGoogle ScholarPubMed
11.Carvalho, AF, Cavalcante, JL, Castelo, MS, Lima, MC. Augmentation strategies for treatment-resistant depression: a literature review. J Clin Pharm Ther. 2007;32(5):415–428.CrossRefGoogle ScholarPubMed
12.DeBattista, C. Augmentation and combination strategies for depression. J Psychopharmacol. 2006;20(suppl 3):11–18.Google Scholar
13.Aronson, R, Offman, HJ, Joffe, RT, Naylor, CD. Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch Gen Psychiatry. 1996;53(9):842–848.CrossRefGoogle ScholarPubMed
14.Crossley, NA, Bauer, M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry. 2007;68(6):935–940.CrossRefGoogle ScholarPubMed
15.Nierenberg, AA, Fava, M, Trivedi, MH, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry. 2006;163(9):1519–1530; quiz 1665.CrossRefGoogle Scholar
16.Bauer, M, Dopfmer, S. Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. J Clin Psychopharmacol. 1999;19(5):427–434.CrossRefGoogle ScholarPubMed
17.Thase, ME. Depression and sleep: pathophysiology and treatment. Dialogues Clin Neurosci. 2006;8(2):217–226.Google Scholar
18.Trivedi, MH, Fava, M, Wisniewski, SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354(12):1243–1252.CrossRefGoogle ScholarPubMed
19.Fava, M, McCall, WV, Krystal, A, et al. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry. 2006;59(11):1052–1060.CrossRefGoogle ScholarPubMed
20.Smith, WT, Londborg, PD, Glaudin, V, Painter, JR. Short-term augmentation of fluoxetine with clonazepam in the treatment of depression: a double-blind study. Am J Psychiatry. 1998;155(10):1339–1345.Google Scholar